MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
74.63
+1.32
+1.80%
Pre Market: 75.00 +0.37 +0.50% 08:49 08/11 EDT
OPEN
72.77
PREV CLOSE
73.31
HIGH
74.75
LOW
72.48
VOLUME
4.33K
TURNOVER
0
52 WEEK HIGH
90.87
52 WEEK LOW
43.18
MARKET CAP
6.23B
P/E (TTM)
-132.6048
1D
5D
1M
3M
1Y
5Y
1D
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped?
Simply Wall St · 13h ago
Weekly Report: what happened at PTCT last week (0803-0807)?
Weekly Report · 1d ago
Have PTC Therapeutics Insiders Been Selling Stock?
Simply Wall St · 2d ago
Top 3 Health Care Stocks You'll Regret Missing This Quarter
Benzinga · 08/04 10:04
PTC Therapeutics (PTCT) Is Down 11.5% After Raising 2026 Outlook And Boosting Profitability - Has The Bull Case Changed?
Simply Wall St · 08/03 16:19
Weekly Report: what happened at PTCT last week (0727-0731)?
Weekly Report · 08/03 10:26
Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)
TipRanks · 08/03 08:45
PTC Therapeutics (PTCT) Stock Drops As Profit Surge Meets Launch Concentration Risk
Simply Wall St · 07/31 22:31
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.